Two common prostate conditions, benign prostatic hyperplasia (BPH) and prostate cancer, can cause similar urinary symptoms, but they are fundamentally different diseases requiring different approaches. BPH is non-cancerous enlargement of the prostate gland affecting many men as they age, while prostate cancer involves the growth of malignant cells. Understanding these distinctions helps you recognise when to seek specialist evaluation and what to expect during diagnosis.
Quick answer BPH is a benign growth of the prostate’s inner (transition) zone that squeezes the urethra and usually causes urinary symptoms. Prostate cancer is a malignant growth that mostly starts in the outer (peripheral) zone and is often silent early on. Both can raise PSA. BPH does not turn into cancer or raise cancer risk, yet a man can have both. Only a structured work-up, ending in MRI-guided biopsy when needed, can confirm cancer.
| Feature | BPH | Prostate cancer |
|---|---|---|
| What it is | Non-cancerous growth of prostate tissue | Malignant growth that can spread |
| Where it starts | Transition zone, around the urethra | Mostly the peripheral zone, the outer gland |
| Early symptoms | Usually present: frequency, weak stream | Often none in the early stages |
| Urinary symptoms | Early and prominent | Usually later, if at all |
| PSA | Can be raised because a larger gland makes more PSA | Can be raised; often higher or rising faster |
| Can it spread? | No | Yes, to bones and other organs if untreated |
| Raises the other’s risk? | Does not increase prostate cancer risk | Not applicable |
| Goal of treatment | Relieve symptoms, protect bladder and kidneys | Control or remove the cancer; depends on stage |
What Is the Difference Between Prostate Cancer and BPH?
Benign prostatic hyperplasia (BPH) is an age-related, non-cancerous enlargement of the prostate gland that causes urinary symptoms but does not become cancer. Prostate cancer, by contrast, involves malignant cells that can grow, spread, and pose serious health risks if left untreated. Both conditions may cause similar warning signs, including difficulty urinating, increased frequency of urination, and weak urine flow, which is why many men confuse them. The key distinction is that BPH cannot transform into cancer, and prostate cancer is never caused by BPH alone. Your symptoms alone cannot tell you which condition you have; only diagnostic testing can confirm the diagnosis. This overlapping presentation underscores the importance of proper medical evaluation rather than self-diagnosis.
Understanding Benign Prostatic Hyperplasia (BPH)
Benign prostatic hyperplasia is the non-cancerous enlargement of the prostate gland, extremely common in older men, and caused by age-related hormonal changes rather than infection or cancer. The prostate naturally grows throughout a man's lifetime, and the hormone DHT (dihydrotestosterone) drives this growth. As the gland enlarges, it can squeeze the urethra, restricting urine flow and causing lower urinary tract symptoms (LUTS). BPH affects quality of life through nocturia (nighttime urination), daytime frequency, urgency, weak stream, and incomplete emptying. Importantly, BPH does not increase your risk of prostate cancer, though the two may coexist. According to the American Urological Association, BPH symptoms worsen gradually and may plateau or even improve with time. The condition is manageable through lifestyle changes, medications, or minimally invasive procedures if symptoms significantly impact daily life.
Understanding Prostate Cancer
Prostate cancer occurs when malignant cells develop in the prostate gland and can grow locally, spread to nearby tissues, or metastasize to distant organs such as bone or lymph nodes. Unlike BPH, which is non-cancerous, prostate cancer poses a direct threat to health and requires timely intervention. According to the National Cancer Institute, prostate cancer is one of the most common cancers in men, particularly in those over 65. Many early-stage prostate cancers grow slowly and may cause no symptoms, which is why screening in asymptomatic men is sometimes recommended depending on age and risk factors. Advanced prostate cancer can cause pelvic pain, blood in urine or semen, erectile dysfunction, and bone pain if it has metastasized. The Gleason score and PSA (prostate-specific antigen) level help doctors grade aggressiveness and guide treatment strategy.
Symptoms: What Points to BPH, What Should Raise Suspicion
Common BPH symptoms
Most men with BPH notice some of these, and they usually build slowly:
- Needing to urinate often, especially at night
- A slow, weak or stop-start stream
- Hesitancy before the stream begins
- A feeling that the bladder has not fully emptied
- Sudden urgency or dribbling after finishing
Doctors grade how much these bother you with the International Prostate Symptom Score (IPSS), a short questionnaire.
Symptoms that are more suggestive of prostate cancer
Early prostate cancer rarely announces itself, and urinary or sexual symptoms usually appear only in later stages. Signs that should prompt a prompt evaluation include:
- Blood in the urine or semen
- Persistent pain in the lower back, hips or pelvis, or bone pain
- New erection difficulties
- Unexplained weight loss or fatigue
The practical lesson: urinary symptoms alone cannot separate the two, because cancer and BPH can share them. Tests do that job.
PSA: Why a High Number Does Not Mean Cancer
PSA is a protein made by prostate cells, normal and malignant. A larger BPH gland makes more of it, and infection or inflammation can raise it too, so a high PSA cannot tell BPH from cancer by itself. The reverse also holds: some men are diagnosed with prostate cancer despite a PSA in the normal range. Urologists therefore look beyond the single value:
| PSA clue | What it adds |
|---|---|
| PSA density (PSA ÷ prostate volume) | Adjusts for a big BPH gland. 0.15 ng/mL/cc is the conventional alarm level, but it is a probability modifier, not a rule, and performs less well in very large prostates. |
| Free-to-total PSA ratio | The share of free PSA is lower in cancer than in BPH. In one study of men with PSA 2.6 to 10 ng/mL, the average ratio was 0.14 with cancer versus 0.22 with benign biopsies. |
| Trend over time | A rapid rise or a very high value raises suspicion of cancer. |
PSA is also the usual entry point for screening. If you are weighing a check-up, our guide to preventive health screening for men over 40 explains what a sensible schedule looks like.
How Doctors Tell Them Apart: The Diagnostic Pathway
A careful work-up moves from simple to precise. Each step either reassures or narrows the question:
-
History and symptom score. Your urologist maps urinary symptoms, family history, medicines and any infection, and records an IPSS.
-
Digital rectal exam (DRE). BPH typically feels like a smooth, evenly enlarged gland, while hard or irregular areas raise concern (Dr Yusuf Saifee’s clinic guide).
-
PSA with density and free PSA. Interpreted together, as described above, and repeated if an infection may have inflated the first value.
-
Urine-flow and bladder tests. Uroflowmetry and urodynamics show whether the symptoms come from true obstruction, which guides BPH treatment rather than the cancer question.
-
Biopsy, when indicated. Tissue is the only way to confirm cancer and grade it.
Can You Have Both BPH and Prostate Cancer?
Yes. BPH does not turn into cancer and does not raise your cancer risk, but both are common in older men, so they often coexist by chance. This is why tissue removed during BPH surgery is sent for histopathology: the occasional cancer found incidentally in transition-zone tissue is picked up that way. Treating the benign problem never replaces cancer evaluation when the signs call for it.
When to See a Urologist
- Night-time urination or a weak stream that disturbs sleep or daily life
- A flagged or steadily rising PSA, even without symptoms
- Blood in urine or semen
- Bone pain, unexplained weight loss, or a family history of prostate cancer
- Inability to pass urine at all: this is an emergency, so go to the nearest emergency department.
Urinary retention is not rare in later life: one review estimates it affects about 10% of men aged 80 and older
Prostate Cancer and BPH Care at Meitra Hospital, Kozhikode
Meitra’s Centre for Nephro-Urosciences combines nephrology and urology under one roof, and it runs a dedicated Prostate Clinic alongside Andrology, Stone and Kidney Transplant clinics. For the question in this article, the relevant pieces are:
- Diagnostics on campus: multichannel urodynamics, TRUS-guided prostate biopsy and a 128-slice CT scanner, all listed on the centre’s page. Prostate MRI is arranged through Meitra’s Advanced Diagnostic and Interventional Radiology department.
- Specialists: the centre is headed by Dr. Vinugopal (HOD), with Dr. Kiran S as in-charge and senior consultant. Dr. Kiran holds an MCh in Urology and the Fellowship of the Royal College of Surgeons of Edinburgh, with a focus on endourology and laser prostate surgery (Dr. Kiran S).
- Surgery for BPH: Holmium Laser Enucleation of the Prostate (HoLEP) is offered as a key procedure.
- Backup if cancer is found: the same hospital houses medical oncology and the Centre for Blood Diseases, BMT & Cancer Immunotherapy, so a diagnosis does not mean starting over somewhere else.
Why Patients From Kerala, Across India and Abroad Choose Meitra for Prostate Care
Choosing where to be evaluated for a prostate problem is a practical decision as much as a medical one. These are the points patients and families tell us matter, and each can be checked:
- One campus, one coordinated plan. Urodynamics, biopsy, imaging, laser surgery and oncology are within the same hospital, so reports and specialists are not scattered across the city.
- Quality credentials you can verify. Meitra displays NABH accreditation, among others, on its website; ask the hospital for its current accreditation certificates, including JCI and NABL.
- Price transparency. Meitra publishes stent prices and knee implant rates on its website, and the team can give an itemised estimate for a biopsy or HoLEP before you decide.
- Built for outstation and international patients. The website is available in English, Malayalam and Arabic, there is a dedicated International Patient desk, a free second-opinion request form, and insurance/TPA information.
- Second opinion without commitment. If you already have a PSA report, MRI or biopsy result, the team can review it first.
Conclusion
BPH and prostate cancer share symptoms and a PSA test, but they are different diseases with different origins, risks and treatments. BPH is common, benign and very treatable. Prostate cancer is often silent early and is best caught through structured testing: PSA read in context, MRI first, and biopsy when the picture demands it. If you have urinary symptoms, a flagged PSA, or any red flag listed above, do not wait or self-diagnose. A single consultation, with the right tests in the right order, usually replaces weeks of worry with a clear answer.
Have a PSA report or symptoms you are unsure about? Chat with the Meitra assistant on WhatsApp for guidance on the next step.
Medical disclaimer: This article is for general information and education only. It is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified doctor about your symptoms, test results and treatment options. Do not delay or disregard medical advice because of something you have read here. If you cannot pass urine or are in severe pain, seek emergency care immediately.
